NICE endorses CSL Vifor’s sparsentan for IgA nephropathy in adults
The UK's National Institute for Health and Care Excellence (NICE) has issued final draft guidance endorsing the use of CSL…
All articles by
-
-
FDA approves GSK’s Nucala to treat COPD
GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as an…
-
Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection
Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting renal, cardiovascular and metabolic conditions such as chronic…
-
Paratek expands commercial portfolio with Optinose
Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product offerings. The companies signed…
-
Lilly’s Kisunla marketing for Alzheimer’s authorised in Australia
Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for Kisunla (donanemab) to treat…
-
Orionis and Genentech link on oncology small-molecule glue medicines
Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech, focusing on the discovery and development of small-molecule monovalent glue…
-
Viz.ai, Sanofi and Regeneron to link for COPD management
Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution…
-
BioNTech to invest up to $1.34bn in UK R&D
BioNTech has made a grant agreement with the UK government to expand its research and development (R&D) activities for medicines,…
-
FDA to restrict Covid-19 booster doses to older adults
The US Food and Drug Administration (FDA) is set to restrict Covid-19 booster doses to older adults and those at…
-
Skye and Arecor to develop higher formulation of CB1 inhibitor
Skye Bioscience has partnered with Arecor Therapeutics to develop a higher formulation of the former’s obesity candidate nimacimab, a cannabinoid receptor…